Recent clinical aspects of hyperprolactinemia induced by antipsychotics

Reviews on Recent Clinical Trials

Volumn 6, Issue 1, 2011, Pages 52-63

  Milano, Walter ^a   D'Acunto, Cosimo Walter ^b   de Rosa, Michele ^a   Festa, Michela ^b   Milano, Luca ^a   Petrella, Claudio ^a   Capasso, Anna ^b  

^a Mental Health Unit   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antipsychotics; Hyperprolactinemia; Prolactin

Indexed keywords

AMISULPRIDE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; CIMETIDINE; CLOZAPINE; DOPAMINE; ESTROGEN; HALOPERIDOL; METHYLDOPA; METOCLOPRAMIDE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PERGOLIDE; QUETIAPINE; RANITIDINE; RESERPINE; RISPERIDONE; SEROTONIN; VERAPAMIL;

ARTICLE; BIPOLAR DISORDER; CANCER RISK; DOPAMINERGIC ACTIVITY; FOOD INTAKE; HOMEOSTASIS; HUMAN; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNITY; NEUROTRANSMISSION; NONHUMAN; OSTEOPOROSIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROLACTIN RELEASE; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEXUAL BEHAVIOR; STRESS; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPERPROLACTINEMIA; PROLACTIN; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 78650950212     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488711793980138     Document Type: Article

References (114)

1. Prabhakar VK, Davis JR. Hyperprolactinaemia. Best P. And R Clin Obst Gynaecol 2008; 22(2): 341-53.
2. Freeman ME, Kanyicska B, Nagy G. Prolactin: structure function and regulation of secretion. Physiol Rev 2000; 80: 1523-631.
3. Friesen H. Guyda H, Hwang P, Tyson JE, Barbeau A. Functional evaluation of prolactin secretion: a guide to therapy. J Clin Invest 1972; 51: 706-09.
4. Hummel BC, Brown GM, Hwang P, Friesen H. Human and monkey prolactin and growth hormone: separation of polymorphic forms by isoelectric focusing. Endocrinol 1975; 97: 855-867.
5. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin: high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42: 175-92.
6. Holt RI. Medical causes and consequences of hyperprolactinemia. A context for psychiatrists. J Psychofarmacol 2008; 22: 28-37.
7. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 2008; 22: 12-19.
8. Harris J, Stanford PM, Oakes SR, Ormandy CJ. Prolactin and prolactin receptor: new targets of an old hormone. Ann Med 2004; 36: 414-25.
9. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2008; 29: 64-73.
10. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28(1 Suppl): 53-67.
11. Halbreich U, Kahn L. Hyperprolactinemia and schizophrenia: mechanism and clinical aspect. J Psychiatr Pract 2003; 9(5): 344-53
12. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia. Mechanisms clinical features and management. Drugs 2004; 64: 2291-314.
13. Byerly M, Suppes T, Tran Q, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patiens with schizophrenia spectrum or bipolar spectrum disorders. J Clin Psychopharmacol 2007; 27: 639-61.
14. La Torre D, Falorni A. Pharmacological causes of hyperprolactinaemia. Ther Clin Risk Manag 2007; 3: 929-51.
15. Montejo AL. Prolactin awarennes: an essential consideration for fisical health in schizophrenia. Eur Neurophycopharmacol 2008; 18: S108-S114.
16. Kohen D, Wildgust HJ. The evolution of hyperprolactinemia as an entity in psychiatric patients. J Psychopharmacol 2008; 22 Suppl: 6-11.
17. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin inhibitor. Endo Rev 2001; 22: 724-63.
18. Konarzewaska B, Wolczynski S. Effects of olanzapine and risperidone on reproductive hormones psychophatology and sexsual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2008; 34: 129-39.
19. Kinon B, Anl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapina. Psychoneuroendocrinology 2006; 31: 577-88.
20. O'Keane V. Antipsychotic-induced hyperprolactinaemia hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008; 2 (2 Suppl.): 70-5.
21. O'Keane V, Meaney M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005; 25(1): 26-31.
22. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002; 181: 49-55.
23. Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry 2000; 61 Suppl 3: 10-15.
24. Colao A, Lombardi G. Growth-hormone and prolactin exess. Lancet 1998: 352: 1455-61.
25. De Rosa M, Zarrilli S, Di Sarno A, et al. Hyperprolactinemia in man: clinical and biochimical features and response to treatment. Endocrine 2003; 20: 75-82.
26. Verhelst J, Abbs R. Hyperprolactinaemia phatophisiology and management. Treat Endocrinol 2003; 2(1): 23-32.
27. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169(6): 575-81.
28. Molitch ME. Drugs and prolactin. Pitutary 2008; 11: 209-18.
29. Bushe C, Shaw M, Peveler C. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22(2 Suppl): 46-55.
30. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinemia in woman: pathophysiology severity and consequences. Selective literature review. Br J Psychiatry 2003; 182: 199-294.
31. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: overview. Psychoneuroendocrinology 2003; 28(2 Suppl): 1-16.
32. Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spect 2007; 12(3 Suppl. 4): 1-13.
33. th edition April 2001 (http://www.mentalhealth.com/book/p40-sc02.html). 2001.
34. Kleinberg DL, Frantz AG. Human prolactin: measurement in plasma by vitro bioassay. J Clin Invest 1971; 50(8): 1557-68.
35. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004; 65(11): 1491-8.
36. Bushe C, Shaw M. Prevalence of hyperprolactinemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007; 21(7): 768-73.
37. Johnsen E, Kroken RA, Abaza M. Antipsychotic-Induced hyperprolactinemia. A Crosssectional survey. J Clin Psychopharmacol 2008; 28: 686-90.
38. Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. A J Psychiatry 2005; 162: 162-7.
39. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80(8): 1050-7.
40. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184: 503-8.
41. Smith S, Wheeler MJ, Murray R. The effects of antipsychotic induced hyperprolactinemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002; 22(2): 109-114.
42. Roke Y, van Harten PN, Boot AN, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adol Psychopharcol 2009; 19(4): 403-14.
43. Correll CU. Effect of hyperprolactinaemia during development in child and adolescent. J Clin Psychiatry 2008; 69(8): 24.
44. Aichhorn W, Whitwoorth AB, Weiss EM, Marlsteiner J. Secondgeneration antipsychotics. Is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drugs Saf 2006; 29(7): 587-98.
45. Troost PW, Lahuis BE, Hermans MH. Prolactin release in children treated with risperidone. J Clin Psychopharmacol 2007; 27: 52-7.
46. Staller J. The effect of long-term antipsychotic treatment on prolactin. J Child Adol Psychopharm 2006; 16(3): 317-26.
47. Stevens J, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapina. J Child Adol Psychopharm 2005; 15(6): 893-900.
48. Jakovljevic M, Pivac N, Mihaljevic-Peles A, et al. The effects of olanzapine and fluphenazine on plasma cortisol prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(2): 399-402.
49. Bushe C, Yeomans D, Floyd T, Smith S. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with typical and atypical antipsychotics. J Psychopharmacol 2008; 22(2 Suppl): 56-62.
50. Crockett A, Goldstein M, Bushe C. How has NICE guidelines affected prescribing in depot clinic schizophrenia outpatients? The Dewsbury experience. British Association of Psychopharmacology 2005 Summer Meeting 24-27 July 2005; Harrogate UK. 2005.
51. Paparrigopoulos T, Liappas J, Tzavellas E, Mouriklis I, Soldatos C. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuro-Psychopharmacol Biol Psychiatry 2007; 31(1): 92-6.
52. Kopecek M, Bares M, Svarc J, Dockery C, Horácek J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol 2004; 25(6): 419-22.
53. Kopecek M, Bares M, Horacek J, Mohr P. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. Neuro Endocrinol Lett 2006; 27(6): 803-6.
54. Lee BH, Kin YK. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol. Biol Psychiatry 2006; 30(4): 658-62.
55. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005; 66(6): 761-7.
56. Schooler N, Rabinowitz J, Davidson M., et al. Early Psychosis Global Working Group. Risperidone and haloperidol in firstepisode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162(5): 947-53.
57. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15(1): 111-7.
58. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole an antipsychotic with a novel mechanism of action and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60(7): 681-90.
59. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley AJ. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17(5): 407-418.
60. Wong J, Seeman MV. Prolactin menstrual irregularities quality of life. Schizophr Res 2007; 91(1-3): 270-271.
61. Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59 (12): 1147-1154.
62. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole Study Group. Aripiprazole for treatment resistant schizophrenia: results of a multicenter randomized doubleblind comparison study versus perphenazine. J Clin Psychiatry 2007; 68(2): 213-223.
63. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004; 65(11): 1491-1498.
64. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized double-blind fixed-dose study. J Clin Psychopharmacol 2008; 28 (4): 392-400.
65. Abilify SpC: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ abilify/H-471-PI-en.pdf
66. Clozaril SpC http://emc.medicines.org.uk/emc/assets/c/html/ DisplayDoc.asp?DocumentID=1277
67. Seroquel SpC: http://emc.medicines.org.uk/emc/assets/c/html/ DisplayDoc.asp?DocumentID=2295
68. Zyprexa SpC: http: //www.emea.europa.eu/humandocs/Humans/EPAR/zyprexa/zyprexa.htm/H-115-PI-EN[1].pdf
69. Svestka J, Synek O, Tomanová J, Rodáková I, Cejpková A. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007; 28(6): 881-8.
70. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine olanzapine risperidone or haloperidol. J Clin Psychiatry 2004; 65(1): 57-61.
71. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 2003; 61(2-3): 123-136.
72. Schlösser R, Gründer G, Anghelescu I, et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002; 46(1): 33-40.
73. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy clinical response and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4): 514-20.
74. Meltzer H. Serotonergic dysfunction in depression. Br J Psychiatry 1989; Suppl. Dec: 25-31.
75. Thomasson-Perret N, Penelaud PF, Theron D, Gautteganges S, Mocaer E. Markers D2 and D3 receptor activity in vivo: PET scan and prolactin. Therapie 2008; 63(3): 237-42.
76. Young R, Lawford B, Barnes M, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Brit J Psychiatry 2004; 185: 147-51.
77. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 158: 360-9.
78. Maguire GA. Prolactin elevation with antipsychotic medications: mechanism of action and clinical consequences. J Clin Psychiatry 2002; 63 (4 suppl): 56-62.
79. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162(5): 1010-1012.
80. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactine levels by atypical antipsychotics. Am J Psych 2002; 159: 133-5.
81. Lambert M, Haro JM, Novick D. Olanzapine vs other antipsychotics in actual out-patient setting: six months tolerability result from the europian schizophrenia out-patient health outcomes study. Acta Psychiatr Scan 2005; 111: 232-43.
82. Bobes J, Garcia-portilla MP, Rejas J. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone olanzapina quetiapina or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29: 125-47.
83. Kinon BJ, Gilmore JA, Blake DS, Dean RA, Liu H. Preliminary exploration of the prevalence of hyperprolactinemia and reproductive hormone reduction during antipsychotic drug treatment. International Congress on Schizophrenia research (ICSR); 4/28 -5/2/2001 Whistler British Columbia (Canada) 2001.
84. Greenman Y, Tordjman K, Stern N. Increase in body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol 1998; 48(5): 547-53.
85. Baptista T, Lacruz A, Meza T, et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 2001; 46(9): 829-34.
86. Cabrera R, Mayor P, Fernández-Ruiz J, Calle C. Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia. Mol Cell Endocrinol 1988; 58(2-3): 167-73.
87. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain diabetes mellitus and lipid abnormalities. Can J Psychiatry 2001; 46(3): 273-81.
88. World Health Organization. Prevention and management of osteoporosis. WHO Techical Report Series 921 Geneve 2003.
89. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007; 21: 109-22.
90. Kishimoto T, Watanabe K. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res 2005; 77(1): 113-5.
91. Misra M, Papakostas GI, Klibaniski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65(12): 1607-18.
92. Becker D, Liver O, Mester R. Risperidone but not olanzapina decrease bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64: 761-6.
93. Stubbs B. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: consideration in relation to bone mass density. J Psych Ment Heart Nurs 2009; 16: 838-42.
94. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28: 97-108.
95. Peveler CR. Antipsychoticts and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008; 22(2): 98-103.
96. Rey-Sanchez P, Lavado-Garcia J. Ultrasone bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol Clin Exp 2009; 24: 49-54.
97. Howard L, Kirkwood G, Leese M. Risk of hip frature in patients with history of schizophrenia. Brit J Psychiatry 2007; 190: 129-34.
98. Lissoni P, Bignami A. Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer. Int J Biol Markers 2005; 20(2): 123-5.
99. Tworoger SS. Eliassen AH. Plasma prolactin concentration and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-19.
100. Hankinson SE, Willett WC. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Nat Cancer Inst 1999; 91: 629-34.
101. Dalton SO, Johansen C, Poulsen AH, Friis S. Cancer risk among uses of neuroleptic medication: a population-based cohort study. Brit J Cancer 2006; 95: 934-9.
102. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26(6); 748-58.
103. Foley K, Kast RE. Review of evidence that post-transplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate. Gen Hosp Psychiatry 2006; 28(3): 230-33.
104. MacMaster FP, El-Sheikh R, Upadhyaya AR, Nutsche J, Rosenberg DR, Keshavan M. Effect of antipsychotics on pituitary gland volume in treatment-naïve first-episode schizophrenia: a pilot study. Schizophr Res 2007; 92(1-3): 207-10.
105. Casanueva FF, Molitch ME, Schlechte JA. Guidelines of the Pituitary Society fort the diagnosis and management of prolactinomas. Clin Endocrinol 2006; 65: 265-73.
106. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacology 2008; 22(2): 90-97.
107. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26(1): 25-40
108. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neurolpetic-treated patients. Acta Psychiatr Scand Supp 1987; 334: 1-100.
109. Milano W, Milano L, Petrella C, Capasso A. Aripripazolo reduces risperidone-induced hyperprolactinemia. Pharmacologyonline 2008; 1: 1-5.
110. Kinon B, Anl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapina. Psychoneuroendocrinology 2006; 31: 577-88.
111. Cavallaro R, Cocchi T, Angelone S. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65(2): 187-190.
112. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 2007; 356(1): 29-38.
113. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356(1): 39-46.
114. Miller K. Management of hyperprolactinemia in patients receving antipsychotics. CNS Spectrum 2004; 9 (Suppl 7): 28-32.